ELEFTHA 440MG INJECTION

About

Eleftha 440mg Injection is a monoclonal antibody therapy specifically designed to target and inhibit the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in certain types of cancer cells. By binding to HER2, Eleftha prevents the receptor from signaling cell growth and division, thereby inhibiting tumor proliferation and promoting apoptosis (programmed cell death). This targeted therapy is a cornerstone in the treatment of HER2-positive breast cancer and gastric cancer, offering a more precise approach to treatment with potentially fewer side effects compared to conventional chemotherapy. It is administered intravenously, often in combination with other chemotherapeutic agents, as part of a comprehensive cancer treatment regimen. Eleftha significantly improves patient outcomes by slowing disease progression, reducing recurrence rates, and enhancing overall survival in eligible patients.

Uses

• Treatment of HER2-positive breast cancer.
• Management of HER2-positive metastatic gastric cancer.
• Adjuvant therapy for early-stage HER2-positive breast cancer.
• Neoadjuvant treatment for HER2-positive breast cancer.

Directions For Use

Administer intravenously under the supervision of a healthcare professional. Follow the prescribed dosing regimen.

Benefits

• Targets specific cancer cells.
• Improves survival rates in HER2-positive cancers.
• Reduces tumor growth and progression.
• Can be used in combination with chemotherapy.
• Offers a personalized treatment approach.
• Enhances disease-free survival.

Side Effects

• Infusion-related reactions (fever, chills)
• Nausea
• Diarrhea
• Fatigue
• Headache
• Cardiotoxicity (heart problems)
• Neutropenia
• Anemia
• Rash
• Muscle pain
• Peripheral neuropathy
• Pulmonary toxicity (rare)

Safety Measures

• Alcohol - Alcohol consumption should be avoided or minimized during cancer treatment as it can exacerbate side effects and impact overall health.
• Pregnancy - Contraindicated during pregnancy due to severe fetal harm. Use effective contraception during and for 7 months after treatment.
• Breastfeeding - Avoid breastfeeding during treatment and for 7 months after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with pre-existing liver conditions. Monitor liver function tests regularly.
• Kidney - Use with caution in patients with severe renal impairment. Monitor kidney function closely.
• Lung - Use with extreme caution in patients with pre-existing lung conditions or a history of pulmonary toxicity. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.